Key facts
- Zhongzhi Biotechnologies’s last known valuation is $63.0M (Dec 2024).
- It has raised $25.8M; the latest was Later Stage VC ($22.8M) in Dec 2024.
- Notable investors include Shengyu Investment, Shinva Medical Instrument Company.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Zhongzhi Biotechnologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Zhongzhi Biotechnologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zhongzhi Biotechnologies
Manufacturer of RNA-based in vitro diagnostic kits designed for pathogen detection in respiratory, reproductive, and gastrointestinal infections. The company focuses on developing, producing, and selling diagnostic reagents, instruments, and consumables to enhance molecular diagnostics.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2011
- Employees
- 145
- Website
- zhongzhibio.com/
- Ownership
- Privately Held (backing)
Zhongzhi Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zhongzhi Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zhongzhi Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.